Chiral Technologies Inc
Company Description
Chiral Technologies, Inc. is a subsidiary of Daicel Corporation, the global market leader in enantioselective chromatography, offering the most extensive portfolio of chiral stationary phases available on the market. Enantioselective chromatography is essential to accelerate drug discovery and development processes. Scientists in the pharmaceutical, agricultural and food industries, universities, and government agencies rely on our expertise in enantioselective chromatography to separate chiral molecules into single enantiomers in research and development departments, and QC laboratories to initiate pre-clinical trials.
Chief Chromatographic Techniques Supported
- High-Performance Liquid Chromatography (HPLC)
- Ultra-High Performance Liquid Chromatography (UHPLC)
- Supercritical Fluid Chromatography (SFC)
- Simulated Moving Bed (SMB) technique
Markets Served
Chiral Technologies serves the North and Latin American markets through Chiral Technologies Inc. (West Chester, Pa.), the European market through Chiral Technologies Europe SAS (Illkirch, France), and the Asian market through Daicel Chiral Technologies India and Daicel Chiral Technologies China, all wholly owned subsidiaries of Daicel Corporation.
Major Products/Services
Daicel chiral columns:
- Revolutionary immobilized CSPs
- Columns packed with sub-2 and 3-µm particles are available for rapid analyses of drug candidates.
- Bulk chiral stationary phases are supplied for process-scale chiral chromatography.
- The company also provides analytical method development and custom separation services.
Facility
Chiral Technologies' headquarters, including a state-of-the-art technical center, are located in West Chester, PA.
Chiral Technologies, Inc.
800 North Five Points Road
West Chester, PA 19380
TELEPHONE
(610) 594-2100
or 800 6CHIRAL
FAX
(610) 594-2325
WEB SITE
NUMBER OF EMPLOYEES
22
YEAR FOUNDED
1990
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
